Fda accepts dupixent® (dupilumab) for priority review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Fda a ccepts dupixent ® (dupilumab) for priority review in c hildren a ged 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis

REGN Ratings Summary

REGN Quant Ranking